[The perioperative safety analysis of conversion therapy for liver cancer: a single-center retrospective study].

Résumé

To investigate the perioperative safety of patients with hepatocellular carcinoma (HCC) undergoing conversion therapy followed by sequential surgical resection. This study was designed as a retrospective case series. Clinical and pathological data were retrospectively collected from 45 patients with initially unresectable HCC who received conversion therapy followed by surgical treatment at the Department of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, between January 2021 and April 2023. The cohort comprised 41 males and 4 females, with an age((IQR)) of 54.5(12.5)years (range: 31 to 74 years). According to the Child-Pugh classification, 44 patients were classified as grade A and one as grade B. The median maximum tumor diameter was 8.05(5.82)cm (range: 4.2 to 19.2 cm). Regarding the China Liver Cancer staging system: 24 cases (53.3%) were at stage Ⅰb, 5 cases (11.1%) at stage Ⅱa, 10 cases (22.2%) at stage Ⅱb, and 6 cases (13.4%) at stage Ⅲa. The clinical characteristics, efficacy and adverse reactions of conversion therapy, as well as perioperative and postoperative follow-up outcomes were analyzed. Overall survival (OS) and disease-free survival (DFS) curves were plotted using the Kaplan-Meier method. For comparion of survival rates among the three groups, if the initial value was